HC Wainwright Estimates Geron’s Q4 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Geron in a research note issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.05 EPS and FY2028 earnings at $0.35 EPS.

A number of other research firms have also commented on GERN. Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Geron in a research note on Friday, August 9th. StockNews.com upgraded shares of Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partnrs upgraded shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Geron in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Geron currently has an average rating of “Moderate Buy” and a consensus target price of $7.05.

Geron Price Performance

Shares of Geron stock opened at $4.29 on Thursday. The company has a 50-day simple moving average of $4.32 and a two-hundred day simple moving average of $4.30. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of -11.92 and a beta of 0.52. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. During the same quarter in the prior year, the business earned ($0.09) EPS. Geron’s quarterly revenue was up 2941.4% on a year-over-year basis.

Institutional Investors Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in GERN. National Bank of Canada FI raised its stake in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,000 shares during the last quarter. Crewe Advisors LLC raised its position in Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC acquired a new position in Geron during the 1st quarter worth about $34,000. American Trust bought a new stake in shares of Geron in the 1st quarter valued at about $38,000. Finally, Rovin Capital UT ADV acquired a new stake in shares of Geron in the third quarter valued at about $62,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.